Diurnal Adrenal Franchise Takes Shape With Alkindi Launch
With the launch in Germany of Alkindi, Diurnal has kickstarted its plan of offering therapies that treat patients with cortisol deficiency diseases from birth right the way through to old age and the market is potentially a very lucrative one.
You may also be interested in...
With its adrenal insufficiency therapy Alkindi getting established in Europe, the UK biotech is in partnering discussions in the US where approval is expected before the end of the year.
Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create novel gene therapies for cancer, neurological, cardiovascular and autoimmune diseases.
Diurnal has suffered a set-back on its road to approval and commercialization of Chronocort, but analysts still see hope for the product.